[
  {
    "title": "业绩漂亮的药明康德 为何留不住“变心”的股东",
    "href": "http://stock.jrj.com.cn/2022/12/02090437183415.shtml",
    "datetime": "2022-12-02 09:04:55",
    "code": "603259"
  },
  {
    "title": "药明康德大股东又大额减持！",
    "href": "http://stock.jrj.com.cn/2022/11/28171437171309.shtml",
    "datetime": "2022-11-28 17:14:05",
    "code": "603259"
  },
  {
    "title": "股东拟减持不超过2.2% 药明康德A股触及跌停",
    "href": "http://stock.jrj.com.cn/2022/11/28095037169971.shtml",
    "datetime": "2022-11-28 09:50:22",
    "code": "603259"
  },
  {
    "title": "药明康德AH股双双重挫，此前实控人关联方抛大额减持计划",
    "href": "http://stock.jrj.com.cn/2022/11/28093337169895.shtml",
    "datetime": "2022-11-28 09:33:46",
    "code": "603259"
  },
  {
    "title": "药明康德实控人关联方又抛大额减持计划，或为前次延续但减持方式有变",
    "href": "http://stock.jrj.com.cn/2022/11/27082037169075.shtml",
    "datetime": "2022-11-27 08:20:09",
    "code": "603259"
  },
  {
    "title": "30万股民要懵了？2400亿大白马，又突发利空！机构重仓，一年多股价腰斩...",
    "href": "http://stock.jrj.com.cn/2022/11/26143037168883.shtml",
    "datetime": "2022-11-26 14:30:15",
    "code": "603259"
  },
  {
    "title": "药明康德：实际控制人控制的股东及与实际控制人签署一致行动协议的股东拟减持不超过2.2%",
    "href": "http://stock.jrj.com.cn/2022/11/25173937167311.shtml",
    "datetime": "2022-11-25 17:39:49",
    "code": "603259"
  },
  {
    "title": "药明康德前三季赚74亿业绩倍增股价背离 大股东套现22亿市值累计蒸发超2200亿",
    "href": "http://stock.jrj.com.cn/2022/10/31104537098770.shtml",
    "datetime": "2022-10-31 10:45:30",
    "code": "603259"
  },
  {
    "title": "以药明康德（603259.SH/2359.HK）为例，在扰动中持续兑现自身的确定性",
    "href": "http://stock.jrj.com.cn/2022/10/30185237097719.shtml",
    "datetime": "2022-10-30 18:52:42",
    "code": "603259"
  },
  {
    "title": "狂赚美国人的钱，药明康德单季度收入超过100亿",
    "href": "http://stock.jrj.com.cn/2022/10/28174237094372.shtml",
    "datetime": "2022-10-28 17:42:00",
    "code": "603259"
  },
  {
    "title": "大行评级 | 大和：药明康德(2359.HK)上调全年收入增长目标 评级“买入”",
    "href": "http://stock.jrj.com.cn/2022/10/27154937089588.shtml",
    "datetime": "2022-10-27 15:49:47",
    "code": "603259"
  },
  {
    "title": "“CRO一哥”终止H股增发计划，原因：业绩大涨现金充足！",
    "href": "http://stock.jrj.com.cn/2022/10/27083537088164.shtml",
    "datetime": "2022-10-27 08:35:15",
    "code": "603259"
  },
  {
    "title": "10派140元，这家公司拟分红10亿；药明康德拟终止增发H股计划…重要消息还有这些",
    "href": "http://stock.jrj.com.cn/2022/10/27082137088129.shtml",
    "datetime": "2022-10-27 08:21:25",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)第三季度净利润同比增209.11%、2022年收入增长目标调至70-72%",
    "href": "http://stock.jrj.com.cn/2022/10/26191637086776.shtml",
    "datetime": "2022-10-26 19:16:16",
    "code": "603259"
  },
  {
    "title": "药明康德：终止增发境外上市外资股（H股） 第三季净利同比增209%",
    "href": "http://stock.jrj.com.cn/2022/10/26190837086704.shtml",
    "datetime": "2022-10-26 19:08:42",
    "code": "603259"
  },
  {
    "title": "北向资金今日大幅净买入74.72亿元 药明康德净买入额居首",
    "href": "http://stock.jrj.com.cn/2022/10/14173237056530.shtml",
    "datetime": "2022-10-14 17:32:34",
    "code": "603259"
  },
  {
    "title": "药明康德前三季净利润预计倍增 上半年研发投入增六成",
    "href": "http://stock.jrj.com.cn/2022/10/14085837055055.shtml",
    "datetime": "2022-10-14 08:58:00",
    "code": "603259"
  },
  {
    "title": "中泰证券点评药明康德：业绩略超预期，Q3恢复态势显著，看好全年持续高增",
    "href": "http://stock.jrj.com.cn/hotstock/2022/10/14080937054565.shtml",
    "datetime": "2022-10-14 08:09:34",
    "code": "603259"
  },
  {
    "title": "药明康德前三季度盈利预增超100%，葛兰二季度加仓布局",
    "href": "http://stock.jrj.com.cn/2022/10/13104137052142.shtml",
    "datetime": "2022-10-13 10:41:50",
    "code": "603259"
  },
  {
    "title": "药明康德AH股齐拉升 预计Q3单季营收首次突破百亿",
    "href": "http://stock.jrj.com.cn/2022/10/13094537051902.shtml",
    "datetime": "2022-10-13 09:45:24",
    "code": "603259"
  },
  {
    "title": "药明康德：预计Q3单季营收首次超百亿，同比增速创历史新高",
    "href": "http://stock.jrj.com.cn/2022/10/12201537051101.shtml",
    "datetime": "2022-10-12 20:15:20",
    "code": "603259"
  },
  {
    "title": "药明康德2022年前三季度预计净利73.78亿同比增加107% 产能利用率持续提升",
    "href": "http://stock.jrj.com.cn/2022/10/12201137051083.shtml",
    "datetime": "2022-10-12 20:11:10",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：前三季度净利润预增约107.12%、营收预增71.87%",
    "href": "http://stock.jrj.com.cn/2022/10/12182037050711.shtml",
    "datetime": "2022-10-12 18:20:41",
    "code": "603259"
  },
  {
    "title": "药明康德：预计前三季度净利同比增长107%",
    "href": "http://stock.jrj.com.cn/2022/10/12181737050642.shtml",
    "datetime": "2022-10-12 18:17:29",
    "code": "603259"
  },
  {
    "title": "药明康德(603259)：股东减持股份结果",
    "href": "http://stock.jrj.com.cn/2022/09/30181737034689.shtml",
    "datetime": "2022-09-30 18:17:27",
    "code": "603259"
  },
  {
    "title": "【龙虎榜】药明康德9月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/09/13180636991824.shtml",
    "datetime": "2022-09-13 18:06:01",
    "code": "603259"
  },
  {
    "title": "药明康德今日跌停 北向资金净卖出5.69亿元",
    "href": "http://stock.jrj.com.cn/2022/09/13164036991363.shtml",
    "datetime": "2022-09-13 16:40:07",
    "code": "603259"
  },
  {
    "title": "药明康德回应股价大跌：公司一切正常",
    "href": "http://stock.jrj.com.cn/2022/09/13105036990513.shtml",
    "datetime": "2022-09-13 10:50:31",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转换债券获转换发行309.39万股",
    "href": "http://stock.jrj.com.cn/2022/09/05164436974043.shtml",
    "datetime": "2022-09-05 16:44:28",
    "code": "603259"
  },
  {
    "title": "药明康德：上半年收入177亿 同比增68.5%",
    "href": "http://stock.jrj.com.cn/2022/08/26192136942121.shtml",
    "datetime": "2022-08-26 19:21:32",
    "code": "603259"
  },
  {
    "title": "药明康德：发行不超过7843.43万股境外上市外资股获核准",
    "href": "http://stock.jrj.com.cn/2022/08/23162036926364.shtml",
    "datetime": "2022-08-23 16:20:38",
    "code": "603259"
  },
  {
    "title": "药明康德：增发境外上市外资股（H股）获得证监会批复",
    "href": "http://stock.jrj.com.cn/2022/08/22171136921851.shtml",
    "datetime": "2022-08-22 17:11:09",
    "code": "603259"
  },
  {
    "title": "药明康德：增发境外上市外资股（H股）获得中国证监会批复",
    "href": "http://stock.jrj.com.cn/2022/08/22165436921783.shtml",
    "datetime": "2022-08-22 16:54:39",
    "code": "603259"
  },
  {
    "title": "药明康德：药明生基将授权杨森使用其先进的TESSA专利技术",
    "href": "http://stock.jrj.com.cn/2022/08/12110636894337.shtml",
    "datetime": "2022-08-12 11:06:10",
    "code": "603259"
  },
  {
    "title": "药明康德：警示函只针对德勤及时任会计师 不影响公司年报审计意见",
    "href": "http://stock.jrj.com.cn/2022/08/12101536894105.shtml",
    "datetime": "2022-08-12 10:15:15",
    "code": "603259"
  },
  {
    "title": "突发利空！30倍900亿白马股实控人，大举出手！股吧炸锅",
    "href": "http://stock.jrj.com.cn/2022/08/06162336875731.shtml",
    "datetime": "2022-08-06 16:23:05",
    "code": "603259"
  },
  {
    "title": "方正证券点评药明康德：疫情影响逐步褪去，全年收入预期70%左右高增长",
    "href": "http://stock.jrj.com.cn/hotstock/2022/08/01083836857849.shtml",
    "datetime": "2022-08-01 08:38:53",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持62.2万股",
    "href": "http://stock.jrj.com.cn/2022/08/01071236857655.shtml",
    "datetime": "2022-08-01 07:12:51",
    "code": "603259"
  },
  {
    "title": "瑞银：上调药明康德(2359.HK)目标价至175港元 评级“买入”",
    "href": "http://stock.jrj.com.cn/2022/07/28154736850376.shtml",
    "datetime": "2022-07-28 15:47:30",
    "code": "603259"
  },
  {
    "title": "大股东套现超400亿！上半年大赚46亿的药明康德 股价跌麻了 业绩线还管用吗？",
    "href": "http://stock.jrj.com.cn/2022/07/28085636849294.shtml",
    "datetime": "2022-07-28 08:56:20",
    "code": "603259"
  },
  {
    "title": "东吴证券：将药明康德2023-2024年归母净利润预期下调至98.3/124.0亿元，维持“买入”评级",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/28085136849283.shtml",
    "datetime": "2022-07-28 08:51:40",
    "code": "603259"
  },
  {
    "title": "中泰证券点评药明康德：Q2疫情扰动有限，主业持续强劲，全年高增有望持续",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/28084636849256.shtml",
    "datetime": "2022-07-28 08:46:38",
    "code": "603259"
  },
  {
    "title": "新高！药明康德上半年大赚46亿，同比增逾七成",
    "href": "http://stock.jrj.com.cn/2022/07/27083736845854.shtml",
    "datetime": "2022-07-27 08:37:45",
    "code": "603259"
  },
  {
    "title": "药明康德：2022年上半年归母净利同比增加73.29%",
    "href": "http://stock.jrj.com.cn/2022/07/26204636844896.shtml",
    "datetime": "2022-07-26 20:46:54",
    "code": "603259"
  },
  {
    "title": "药明康德2022年上半年净利46.36亿同比增长73.29% 经营管理效率提升",
    "href": "http://stock.jrj.com.cn/2022/07/26195236844723.shtml",
    "datetime": "2022-07-26 19:52:19",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)半年度扣非净利润38.50亿元、同比增长81%",
    "href": "http://stock.jrj.com.cn/2022/07/26173436844117.shtml",
    "datetime": "2022-07-26 17:34:52",
    "code": "603259"
  },
  {
    "title": "药明康德：上半年实现净利润46.36亿元，同比增长73.29%",
    "href": "http://stock.jrj.com.cn/2022/07/26173236844089.shtml",
    "datetime": "2022-07-26 17:32:13",
    "code": "603259"
  },
  {
    "title": "大和：上调药明康德(2359.HK)目标价5%至200港元，维持买入评级",
    "href": "http://stock.jrj.com.cn/2022/07/26144136843441.shtml",
    "datetime": "2022-07-26 14:41:08",
    "code": "603259"
  },
  {
    "title": "药明康德：将2022年全年收入增长目标上调至68-72%",
    "href": "http://stock.jrj.com.cn/2022/07/22093736834668.shtml",
    "datetime": "2022-07-22 09:37:32",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)：2022年全年收入增长目标上调至68-72%",
    "href": "http://stock.jrj.com.cn/2022/07/22060936833781.shtml",
    "datetime": "2022-07-22 06:09:25",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)将2022年全年收入增长目标由65-70%上调至68-72%",
    "href": "http://stock.jrj.com.cn/2022/07/21223536833576.shtml",
    "datetime": "2022-07-21 22:35:28",
    "code": "603259"
  },
  {
    "title": "药明康德拟投资20亿新元在新加坡建立研发和生产基地",
    "href": "http://stock.jrj.com.cn/2022/07/20093336827484.shtml",
    "datetime": "2022-07-20 09:33:30",
    "code": "603259"
  },
  {
    "title": "中信建投评药明康德：持续强化独特业务模式 二季度营收超预期",
    "href": "http://stock.jrj.com.cn/2022/07/17201636818667.shtml",
    "datetime": "2022-07-17 20:16:42",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)拟7月26日召开董事会会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2022/07/12163436803543.shtml",
    "datetime": "2022-07-12 16:34:10",
    "code": "603259"
  },
  {
    "title": "国泰君安证券点评药明康德：业绩超预期，龙头优势显现，维持目标价154.03元",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/12084736802289.shtml",
    "datetime": "2022-07-12 08:47:27",
    "code": "603259"
  },
  {
    "title": "药明康德2022年上半年预计净利46.36亿同比增加73% 不断优化经营效率令产能提升",
    "href": "http://stock.jrj.com.cn/2022/07/12051036801127.shtml",
    "datetime": "2022-07-12 05:10:57",
    "code": "603259"
  },
  {
    "title": "中报打响吃药行情发令枪？3000亿CXO龙头交出超预期答卷",
    "href": "http://stock.jrj.com.cn/2022/07/11213336800620.shtml",
    "datetime": "2022-07-11 21:33:19",
    "code": "603259"
  },
  {
    "title": "药明康德：预计上半年净利约46.36亿元 同比增约73.29%",
    "href": "http://stock.jrj.com.cn/2022/07/11171236799297.shtml",
    "datetime": "2022-07-11 17:12:12",
    "code": "603259"
  },
  {
    "title": "永远在减持的路上 浓眉大眼的药明康德还有多少隐忧点？",
    "href": "http://stock.jrj.com.cn/2022/06/20090536741308.shtml",
    "datetime": "2022-06-20 09:05:00",
    "code": "603259"
  },
  {
    "title": "药明康德700亿套现潮：葛兰3年买了70亿",
    "href": "http://stock.jrj.com.cn/2022/06/17194036739113.shtml",
    "datetime": "2022-06-17 19:40:21",
    "code": "603259"
  },
  {
    "title": "业绩预期乐观却遭投资者“用脚投票” 药明康德昨触及跌停",
    "href": "http://stock.jrj.com.cn/2022/06/14085636726351.shtml",
    "datetime": "2022-06-14 08:56:03",
    "code": "603259"
  },
  {
    "title": "市值一日蒸发300亿，药明康德怎么了？",
    "href": "http://stock.jrj.com.cn/2022/06/13230536725915.shtml",
    "datetime": "2022-06-13 23:05:40",
    "code": "603259"
  },
  {
    "title": "【龙虎榜】药明康德6月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/06/13181036724893.shtml",
    "datetime": "2022-06-13 18:10:02",
    "code": "603259"
  },
  {
    "title": "突发！CXO板块大跌，药明康德开盘跌停；双语直播带货火了，新东方在线股价一度暴涨100%",
    "href": "http://stock.jrj.com.cn/2022/06/13134336723630.shtml",
    "datetime": "2022-06-13 13:43:32",
    "code": "603259"
  },
  {
    "title": "吓懵，3000亿巨头逼近跌停！户均亏损14万，这则消息或成“元凶”，业绩增速下滑且大比例拟减持股来了",
    "href": "http://stock.jrj.com.cn/2022/06/13124336723529.shtml",
    "datetime": "2022-06-13 12:43:35",
    "code": "603259"
  },
  {
    "title": "药明康德港股盘中跌逾10%，拟遭实控人减持不超3%的A股股份",
    "href": "http://stock.jrj.com.cn/2022/06/13105236723275.shtml",
    "datetime": "2022-06-13 10:52:46",
    "code": "603259"
  },
  {
    "title": "药明康德实控人超90亿减持引看空猜想 市值一年缩水1834亿高增业绩恐难持续",
    "href": "http://stock.jrj.com.cn/2022/06/13103336723142.shtml",
    "datetime": "2022-06-13 10:33:01",
    "code": "603259"
  },
  {
    "title": "药明康德竞价跳空低开跌超7% 实控人拟减持不超过3%股份",
    "href": "http://stock.jrj.com.cn/2022/06/13093036722856.shtml",
    "datetime": "2022-06-13 09:30:40",
    "code": "603259"
  },
  {
    "title": "股吧炸锅！3000亿巨头股价暴跌，实控人突抛近百亿大减持！20万股民要慌了？有股东违规减持刚被罚",
    "href": "http://stock.jrj.com.cn/2022/06/11111536721302.shtml",
    "datetime": "2022-06-11 11:15:51",
    "code": "603259"
  },
  {
    "title": "药明康德(603259)：股东减持股份计划",
    "href": "http://stock.jrj.com.cn/2022/06/11092236721268.shtml",
    "datetime": "2022-06-11 09:22:26",
    "code": "603259"
  },
  {
    "title": "【晚间公告全知道】药明康德实控人相关方拟合计减持不超3%股份、北京君正获绍兴韦豪举牌",
    "href": "http://stock.jrj.com.cn/2022/06/10212736720750.shtml",
    "datetime": "2022-06-10 21:27:43",
    "code": "603259"
  },
  {
    "title": "药明康德：实控人相关方拟减持不超3%股份",
    "href": "http://stock.jrj.com.cn/2022/06/10210436720639.shtml",
    "datetime": "2022-06-10 21:04:05",
    "code": "603259"
  },
  {
    "title": "A股异动 | 药明康德涨5% 料第二季度收入仍将实现63%-65%的增长",
    "href": "http://stock.jrj.com.cn/2022/06/06102836704681.shtml",
    "datetime": "2022-06-06 10:28:08",
    "code": "603259"
  },
  {
    "title": "药明康德：预计第二季度收入仍将实现63%-65%的增长",
    "href": "http://stock.jrj.com.cn/2022/06/06090836704339.shtml",
    "datetime": "2022-06-06 09:08:44",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：继续对2022年实现收入增长65-70%的目标充满信心",
    "href": "http://stock.jrj.com.cn/2022/06/05164336703635.shtml",
    "datetime": "2022-06-05 16:43:39",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)2021年度A股权益分派10派5.174元 股权登记日为6月8日",
    "href": "http://stock.jrj.com.cn/2022/06/01181336697646.shtml",
    "datetime": "2022-06-01 18:13:28",
    "code": "603259"
  },
  {
    "title": "药明康德：股东上海瀛翊违规减持 收到行政处罚决定书",
    "href": "http://stock.jrj.com.cn/2022/05/27191036685683.shtml",
    "datetime": "2022-05-27 19:10:28",
    "code": "603259"
  },
  {
    "title": "药明康德：合共约190.58万份股票期权可开始行权",
    "href": "http://stock.jrj.com.cn/2022/05/26092636679801.shtml",
    "datetime": "2022-05-26 09:26:09",
    "code": "603259"
  },
  {
    "title": "违规减持被罚，知名并购基金华杉瑞联为何会被同一块石头绊倒？二级市场减持愈发困难，“并购女王”看好通过",
    "href": "http://stock.jrj.com.cn/2022/05/18194436659798.shtml",
    "datetime": "2022-05-18 19:44:40",
    "code": "603259"
  },
  {
    "title": "证监会2亿元天价罚单也难平散户怒火？三千亿元市值CXO龙头遭违规减持 行业仍处调整中",
    "href": "http://stock.jrj.com.cn/2022/05/15075336648882.shtml",
    "datetime": "2022-05-15 07:53:37",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持76.76万股",
    "href": "http://stock.jrj.com.cn/2022/05/04080736552419.shtml",
    "datetime": "2022-05-04 08:07:15",
    "code": "603259"
  },
  {
    "title": "药明康德2022年第一季度净利16.43亿同比增长9.54% 产能利用率持续提升",
    "href": "http://stock.jrj.com.cn/2022/05/03185036546065.shtml",
    "datetime": "2022-05-03 18:50:43",
    "code": "603259"
  },
  {
    "title": "一季度基金重仓股出炉！贵州茅台、宁德时代、药明康德受追捧",
    "href": "http://stock.jrj.com.cn/2022/04/27223436487040.shtml",
    "datetime": "2022-04-27 22:34:50",
    "code": "603259"
  },
  {
    "title": "东吴证券点评药明康德：Q1业绩符合预期 全年业绩高确定性+高增速",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/27085636481062.shtml",
    "datetime": "2022-04-27 08:56:55",
    "code": "603259"
  },
  {
    "title": "大摩：重申药明康德AH股增持评级 予公司A股目标价174元",
    "href": "http://stock.jrj.com.cn/2022/04/26141536474880.shtml",
    "datetime": "2022-04-26 14:15:07",
    "code": "603259"
  },
  {
    "title": "高盛：药明康德(2359.HK)首季化学业务胜预期，评级买入",
    "href": "http://stock.jrj.com.cn/2022/04/26110636473629.shtml",
    "datetime": "2022-04-26 11:06:14",
    "code": "603259"
  },
  {
    "title": "CRO概念股震荡走强 药明康德大涨超7%",
    "href": "http://stock.jrj.com.cn/2022/04/26103336473097.shtml",
    "datetime": "2022-04-26 10:33:05",
    "code": "603259"
  },
  {
    "title": "港股异动 | 药明康德高开2% 一季度归母净利同比增长9.54%",
    "href": "http://stock.jrj.com.cn/2022/04/26093036472776.shtml",
    "datetime": "2022-04-26 09:30:20",
    "code": "603259"
  },
  {
    "title": "药明康德2021财年全年净利50.93亿元 同比增长72.42%",
    "href": "http://stock.jrj.com.cn/2022/04/25211136467925.shtml",
    "datetime": "2022-04-25 21:11:13",
    "code": "603259"
  },
  {
    "title": "药明康德：2022年一季度实现净利润16.4亿元，同比增长9.54%",
    "href": "http://stock.jrj.com.cn/2022/04/25192236466551.shtml",
    "datetime": "2022-04-25 19:22:29",
    "code": "603259"
  },
  {
    "title": "营利创单季新高，药明康德2022年首季营收同比增超71%",
    "href": "http://stock.jrj.com.cn/2022/04/25184436466095.shtml",
    "datetime": "2022-04-25 18:44:14",
    "code": "603259"
  },
  {
    "title": "没资格将回撤推诿于外因！这位资深基金经理深刻检讨，刚刚大笔减持药明康德",
    "href": "http://stock.jrj.com.cn/2022/04/20200236412190.shtml",
    "datetime": "2022-04-20 20:02:20",
    "code": "603259"
  },
  {
    "title": "药明康德：预计第一季度营收同比增长约71.18%",
    "href": "http://stock.jrj.com.cn/2022/04/11095636299844.shtml",
    "datetime": "2022-04-11 09:56:04",
    "code": "603259"
  },
  {
    "title": "药明康德2022年一季度预计净利16.43亿同比增长约10% 产能利用率持续提升",
    "href": "http://stock.jrj.com.cn/2022/04/10205236294439.shtml",
    "datetime": "2022-04-10 20:52:25",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)预计一季度经调整净利润达20.53亿元 同比增长85.82%",
    "href": "http://stock.jrj.com.cn/2022/04/10161136291275.shtml",
    "datetime": "2022-04-10 16:11:24",
    "code": "603259"
  },
  {
    "title": "药明康德：一季度净利润同比预增9.54%",
    "href": "http://stock.jrj.com.cn/2022/04/10154736291204.shtml",
    "datetime": "2022-04-10 15:47:37",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持83.6万股",
    "href": "http://stock.jrj.com.cn/2022/04/07072536266347.shtml",
    "datetime": "2022-04-07 07:25:08",
    "code": "603259"
  },
  {
    "title": "2021年公募配置从分化转至均衡！主动权益类基金青睐药明康德",
    "href": "http://stock.jrj.com.cn/2022/04/01095536245375.shtml",
    "datetime": "2022-04-01 09:55:32",
    "code": "603259"
  },
  {
    "title": "药明康德（603259.SH/2359.HK）：规模效应显现，盈利跑出加速度",
    "href": "http://stock.jrj.com.cn/2022/03/29090436068593.shtml",
    "datetime": "2022-03-29 09:04:18",
    "code": "603259"
  },
  {
    "title": "东吴证券点评药明康德2021年年报：高景气龙头延续高增速 新业务持续放量带动长期业绩增长",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/25083535040701.shtml",
    "datetime": "2022-03-25 08:35:58",
    "code": "603259"
  },
  {
    "title": "药明康德2021年净利50.97亿同比增长72.19% 董事长李革薪酬2476.38万",
    "href": "http://stock.jrj.com.cn/2022/03/24165134902344.shtml",
    "datetime": "2022-03-24 16:51:58",
    "code": "603259"
  },
  {
    "title": "药明康德2021年营收净利润大增：研发人员2.88万名 研究人员费用仅6.85亿",
    "href": "http://stock.jrj.com.cn/2022/03/24165134902304.shtml",
    "datetime": "2022-03-24 16:51:54",
    "code": "603259"
  },
  {
    "title": "药明康德2021年归母净利润50.97亿元，同比增长72.2%",
    "href": "http://stock.jrj.com.cn/2022/03/24145134896140.shtml",
    "datetime": "2022-03-24 14:51:43",
    "code": "603259"
  },
  {
    "title": "药明康德：公司基本满负荷运转 预计今年净利润增速或仍将超营收增速",
    "href": "http://stock.jrj.com.cn/2022/03/24103434890500.shtml",
    "datetime": "2022-03-24 10:34:04",
    "code": "603259"
  },
  {
    "title": "【挖财报】CXO龙头药明康德净利润增长72.19%，研发人员2.88万占比逾8成，葛兰旗下中欧医疗健康四季度加仓",
    "href": "http://stock.jrj.com.cn/2022/03/24083034887654.shtml",
    "datetime": "2022-03-24 08:30:38",
    "code": "603259"
  },
  {
    "title": "【晚间公告全知道】豫园股份澄清拟收购某酒企的报道不属实！药明康德2021年净利同比增长72.19％",
    "href": "http://stock.jrj.com.cn/2022/03/23213534874666.shtml",
    "datetime": "2022-03-23 21:35:41",
    "code": "603259"
  },
  {
    "title": "药明康德：2021年净利50.97亿元 同比增长72.19%",
    "href": "http://stock.jrj.com.cn/2022/03/23192134871826.shtml",
    "datetime": "2022-03-23 19:21:52",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持38.04万股",
    "href": "http://stock.jrj.com.cn/2022/03/15075334826958.shtml",
    "datetime": "2022-03-15 07:53:21",
    "code": "603259"
  },
  {
    "title": "首发“月报”掀浪潮，医药龙头药明康德在手订单、销售收入创历史新高！受益市场旺销，片仔癀实现“开门红”",
    "href": "http://stock.jrj.com.cn/2022/03/09210934622430.shtml",
    "datetime": "2022-03-09 21:09:37",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：1-2月在手订单、销售收入同比增速均超65% 一季度收入预增65%-68%",
    "href": "http://stock.jrj.com.cn/2022/03/09173934572165.shtml",
    "datetime": "2022-03-09 17:39:27",
    "code": "603259"
  },
  {
    "title": "药明康德：预计2022年第一季度收入同比增长将达到65-68%",
    "href": "http://stock.jrj.com.cn/2022/03/09173834571838.shtml",
    "datetime": "2022-03-09 17:38:45",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)3月23日举行董事会会议审批年度业绩",
    "href": "http://stock.jrj.com.cn/2022/03/09164034556044.shtml",
    "datetime": "2022-03-09 16:40:41",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持42.67万股",
    "href": "http://stock.jrj.com.cn/2022/02/22065734432102.shtml",
    "datetime": "2022-02-22 06:57:18",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：参股公司清晰医疗在联交所主板挂牌上市",
    "href": "http://stock.jrj.com.cn/2022/02/18172134392528.shtml",
    "datetime": "2022-02-18 17:21:38",
    "code": "603259"
  },
  {
    "title": "东吴证券点评药明康德2021年业绩快报：行业龙头持续高景气 CRDMO带动业绩高速增长",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/17090734378459.shtml",
    "datetime": "2022-02-17 09:07:56",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持352.37万股",
    "href": "http://stock.jrj.com.cn/2022/02/17072334378164.shtml",
    "datetime": "2022-02-17 07:23:45",
    "code": "603259"
  },
  {
    "title": "港股异动丨药明康德(2359.HK)高开逾3% 去年大赚50.97亿元 同比增超72%",
    "href": "http://stock.jrj.com.cn/2022/02/16092234362373.shtml",
    "datetime": "2022-02-16 09:22:21",
    "code": "603259"
  },
  {
    "title": "药明康德2021年净利50.97亿同比增长72.19% 订单需求旺盛",
    "href": "http://stock.jrj.com.cn/2022/02/15191134354846.shtml",
    "datetime": "2022-02-15 19:11:10",
    "code": "603259"
  },
  {
    "title": "超跌赛道反弹！2700亿药明康德涨停！新行情来了？",
    "href": "http://stock.jrj.com.cn/2022/02/15184234354719.shtml",
    "datetime": "2022-02-15 18:42:00",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)业绩快报：2021年度净利润升72.19%至50.97亿元",
    "href": "http://stock.jrj.com.cn/2022/02/15170434354147.shtml",
    "datetime": "2022-02-15 17:04:58",
    "code": "603259"
  },
  {
    "title": "药明康德业绩快报：2021年净利同比增长72.19%",
    "href": "http://stock.jrj.com.cn/2022/02/15170034354122.shtml",
    "datetime": "2022-02-15 17:00:08",
    "code": "603259"
  },
  {
    "title": "CRO概念股继续走高 药明康德封板",
    "href": "http://stock.jrj.com.cn/2022/02/15140734353386.shtml",
    "datetime": "2022-02-15 14:07:52",
    "code": "603259"
  },
  {
    "title": "“顶流”药明康德何时能“止血”？",
    "href": "http://stock.jrj.com.cn/2022/02/14084634338787.shtml",
    "datetime": "2022-02-14 08:46:00",
    "code": "603259"
  },
  {
    "title": "药明康德回应股价下挫 业绩增长难打消股东高管减持“疑虑”",
    "href": "http://stock.jrj.com.cn/2022/02/11085634321121.shtml",
    "datetime": "2022-02-11 08:56:00",
    "code": "603259"
  },
  {
    "title": "药明康德回应股价下挫 业绩增长难打消股东高管减持“疑虑”",
    "href": "http://stock.jrj.com.cn/2022/02/11085634426994.shtml",
    "datetime": "2022-02-11 08:56:00",
    "code": "603259"
  },
  {
    "title": "昔日小甜甜，今日牛夫人！葛兰与宁王齐遭谣言“攻打”，谁是砸盘始作俑者？情绪杀跌还是另有其因？",
    "href": "http://stock.jrj.com.cn/2022/02/10211034319654.shtml",
    "datetime": "2022-02-10 21:10:45",
    "code": "603259"
  },
  {
    "title": "药明康德：公司未发现其他需要澄清或回应的媒体报道或市场传闻",
    "href": "http://stock.jrj.com.cn/2022/02/10190234319184.shtml",
    "datetime": "2022-02-10 19:02:51",
    "code": "603259"
  },
  {
    "title": "【龙虎榜】药明康德2月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/10180834318966.shtml",
    "datetime": "2022-02-10 18:08:25",
    "code": "603259"
  },
  {
    "title": "药明康德大跌7.41% 四机构合计卖出22.96亿元",
    "href": "http://stock.jrj.com.cn/2022/02/10163834318418.shtml",
    "datetime": "2022-02-10 16:38:17",
    "code": "603259"
  },
  {
    "title": "药明康德：预计未来不会被纳入UVL名单",
    "href": "http://stock.jrj.com.cn/2022/02/09175334313992.shtml",
    "datetime": "2022-02-09 17:53:37",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)及子公司均未被美国商务部列入“未经证实名单”",
    "href": "http://stock.jrj.com.cn/2022/02/08153234306639.shtml",
    "datetime": "2022-02-08 15:32:14",
    "code": "603259"
  },
  {
    "title": "美国又下黑手！3000亿巨头药明康德一度暴跌近30%，CRO板块滑铁卢，公司盘中紧急回应：有误读！",
    "href": "http://stock.jrj.com.cn/2022/02/08150634306574.shtml",
    "datetime": "2022-02-08 15:06:57",
    "code": "603259"
  },
  {
    "title": "药明康德澄清：未被美国商务部列入“未经证实名单” 不持有药明生物股份",
    "href": "http://stock.jrj.com.cn/2022/02/08141034306382.shtml",
    "datetime": "2022-02-08 14:10:48",
    "code": "603259"
  },
  {
    "title": "午后药明康德A股打开跌停，成交额20亿元",
    "href": "http://stock.jrj.com.cn/2022/02/08133434306261.shtml",
    "datetime": "2022-02-08 13:34:22",
    "code": "603259"
  },
  {
    "title": "AH股价齐跌 药明康德紧急澄清：公司及子公司均未被美国商务部列入“未经证实名单”",
    "href": "http://stock.jrj.com.cn/2022/02/08130934306203.shtml",
    "datetime": "2022-02-08 13:09:48",
    "code": "603259"
  },
  {
    "title": "“药明”系重挫！药明生物跌30%后停牌，药明康德跌停！公司回应来了",
    "href": "http://stock.jrj.com.cn/2022/02/08130334306195.shtml",
    "datetime": "2022-02-08 13:03:05",
    "code": "603259"
  },
  {
    "title": "重磅突发！万亿“宁王”罕见暴跌9%，白酒芯片锂电齐大跌！美国又下黑手？3000亿医药巨头闪崩30%！",
    "href": "http://stock.jrj.com.cn/2022/02/08115234305149.shtml",
    "datetime": "2022-02-08 11:52:20",
    "code": "603259"
  },
  {
    "title": "突发！美商务部下黑手，药明生物暴跌30%，药明康德开盘1分钟跌停！来看公司最新回应",
    "href": "http://stock.jrj.com.cn/2022/02/08114434305115.shtml",
    "datetime": "2022-02-08 11:44:50",
    "code": "603259"
  },
  {
    "title": "药明系个股暴跌，药明康德跳空跌停，港股药明生物最高跌超30%",
    "href": "http://stock.jrj.com.cn/2022/02/08113034305070.shtml",
    "datetime": "2022-02-08 11:30:05",
    "code": "603259"
  },
  {
    "title": "港股药明生物跌超26%，药明康德跌逾20%，A股药明康德跌停",
    "href": "http://stock.jrj.com.cn/2022/02/08094334304675.shtml",
    "datetime": "2022-02-08 09:43:17",
    "code": "603259"
  },
  {
    "title": "港股药明生物、药明康德双双大跌25%，A股药明康德跌停",
    "href": "http://stock.jrj.com.cn/2022/02/08093534304612.shtml",
    "datetime": "2022-02-08 09:35:14",
    "code": "603259"
  },
  {
    "title": "IPO | 清晰医疗通过港交所聆讯，药明康德持股20.83%",
    "href": "http://stock.jrj.com.cn/2022/01/29133134256934.shtml",
    "datetime": "2022-01-29 13:31:06",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据H股奖励信托计划进一步授予奖励",
    "href": "http://stock.jrj.com.cn/2022/01/21170534183096.shtml",
    "datetime": "2022-01-21 17:05:11",
    "code": "603259"
  },
  {
    "title": "药明康德2021年预计净利49.73亿-50.32亿同比增加68%-70% 订单需求旺盛",
    "href": "http://stock.jrj.com.cn/2022/01/18191234170847.shtml",
    "datetime": "2022-01-18 19:12:11",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行7.11万股",
    "href": "http://stock.jrj.com.cn/2022/01/18184234170639.shtml",
    "datetime": "2022-01-18 18:42:16",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：2021年度净利预增68%-70%",
    "href": "http://stock.jrj.com.cn/2022/01/18162734169831.shtml",
    "datetime": "2022-01-18 16:27:59",
    "code": "603259"
  },
  {
    "title": "药明康德：2021年净利同比预增68%-70%",
    "href": "http://stock.jrj.com.cn/2022/01/18162434169816.shtml",
    "datetime": "2022-01-18 16:24:16",
    "code": "603259"
  },
  {
    "title": "药明康德AH股齐涨 公司副董事长预计今年营业额及利润增长较2021年进一步提升",
    "href": "http://stock.jrj.com.cn/2022/01/11101434144754.shtml",
    "datetime": "2022-01-11 10:14:40",
    "code": "603259"
  },
  {
    "title": "CXO泡沫破了？“药茅”药明康德股价呈两市普跌态势",
    "href": "http://stock.jrj.com.cn/2022/01/07110734132730.shtml",
    "datetime": "2022-01-07 11:07:22",
    "code": "603259"
  },
  {
    "title": "迈瑞医疗、凯莱英、药明康德大跌 ！医药股迎“开门黑” “抄底”还是“快逃”？",
    "href": "http://stock.jrj.com.cn/2022/01/05105134123298.shtml",
    "datetime": "2022-01-05 10:51:31",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：高级财务副总裁施明晋升为首席财务官",
    "href": "http://stock.jrj.com.cn/2021/12/31174134093672.shtml",
    "datetime": "2021-12-31 17:41:33",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：部分A股首发募投项目延期及变更资金用途",
    "href": "http://stock.jrj.com.cn/2021/12/31173834093667.shtml",
    "datetime": "2021-12-31 17:38:36",
    "code": "603259"
  },
  {
    "title": "广生堂控股子公司与药明康德签订抗新型冠状病毒小分子口服药3CL蛋白酶抑制剂合作开发合同书",
    "href": "http://stock.jrj.com.cn/2021/12/24195034059305.shtml",
    "datetime": "2021-12-24 19:50:53",
    "code": "603259"
  },
  {
    "title": "贵州百灵(002424.SZ)：近期收到药明康德关于“替芬泰”的实验研究报告",
    "href": "http://stock.jrj.com.cn/2021/12/20210634036660.shtml",
    "datetime": "2021-12-20 21:06:19",
    "code": "603259"
  },
  {
    "title": "股民哭了！一签少赚13万，光伏新能源突然崩了，3000亿白马狂跌9%！央行终于降息！“中植系”暴跌",
    "href": "http://stock.jrj.com.cn/2021/12/20121334033657.shtml",
    "datetime": "2021-12-20 12:13:15",
    "code": "603259"
  },
  {
    "title": "药明康德(2359.HK)涨超8% 公司强调运营一切正常",
    "href": "http://stock.jrj.com.cn/2021/12/16100134023360.shtml",
    "datetime": "2021-12-16 10:01:28",
    "code": "603259"
  },
  {
    "title": "【龙虎榜】药明康德12月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/12/15180734020327.shtml",
    "datetime": "2021-12-15 18:07:30",
    "code": "603259"
  },
  {
    "title": "3500亿市值“药茅”闪崩跌停！这一赛道全线跳水，18万股东被闷杀",
    "href": "http://stock.jrj.com.cn/2021/12/15180134020246.shtml",
    "datetime": "2021-12-15 18:01:45",
    "code": "603259"
  },
  {
    "title": "港股收评 | 生物医药板块暴跌，药明生物、药明康德均跌超19%",
    "href": "http://stock.jrj.com.cn/2021/12/15171934020013.shtml",
    "datetime": "2021-12-15 17:19:59",
    "code": "603259"
  },
  {
    "title": "18万股民“吓懵”！4000亿“药茅”闪崩跌停，港股更是暴跌20%！",
    "href": "http://stock.jrj.com.cn/2021/12/15154934019572.shtml",
    "datetime": "2021-12-15 15:49:40",
    "code": "603259"
  },
  {
    "title": "药明康德回应股价突然跳水 ：公司经营情况一切正常",
    "href": "http://stock.jrj.com.cn/2021/12/15153234019481.shtml",
    "datetime": "2021-12-15 15:32:48",
    "code": "603259"
  },
  {
    "title": "收评：A股三大指数震荡收跌创业板指跌0.87%，CRO板块尾盘跳水，药明康德跌停",
    "href": "http://stock.jrj.com.cn/2021/12/15150334019391.shtml",
    "datetime": "2021-12-15 15:03:24",
    "code": "603259"
  },
  {
    "title": "药明康德尾盘跳水跌停，H股跌超10%，药明生物跌近20%",
    "href": "http://stock.jrj.com.cn/2021/12/15144234019323.shtml",
    "datetime": "2021-12-15 14:42:34",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：参股公司CANbridge于12月10日登陆港交所",
    "href": "http://stock.jrj.com.cn/2021/12/10203533995998.shtml",
    "datetime": "2021-12-10 20:35:49",
    "code": "603259"
  },
  {
    "title": "药明康德、莱美药业等上市公司争抢PROTAC等靶向降解市场 相关开发企业屡获融资",
    "href": "http://stock.jrj.com.cn/2021/11/20194733887393.shtml",
    "datetime": "2021-11-20 19:47:14",
    "code": "603259"
  },
  {
    "title": "IPO | 北海康成通过港交所聆讯，药明康德持股占比10.97%",
    "href": "http://stock.jrj.com.cn/2021/11/18133833871910.shtml",
    "datetime": "2021-11-18 13:38:36",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)遭贝莱德减持178.15万股",
    "href": "http://stock.jrj.com.cn/2021/11/17070233864003.shtml",
    "datetime": "2021-11-17 07:02:07",
    "code": "603259"
  },
  {
    "title": "药明康德，CXO龙头的希望和隐忧",
    "href": "http://stock.jrj.com.cn/2021/11/16082833858334.shtml",
    "datetime": "2021-11-16 08:28:10",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获Computershare Hong Kong Trustees增持17.12万股",
    "href": "http://stock.jrj.com.cn/2021/11/16070833858143.shtml",
    "datetime": "2021-11-16 07:08:41",
    "code": "603259"
  },
  {
    "title": "药明康德股东减持1498.92万股 套现19.45亿 第三季度公司净利8.87亿",
    "href": "http://stock.jrj.com.cn/2021/11/12220133842868.shtml",
    "datetime": "2021-11-12 22:01:53",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：Summer Bloom完成减持1498.918万股",
    "href": "http://stock.jrj.com.cn/2021/11/12174633841682.shtml",
    "datetime": "2021-11-12 17:46:50",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获贝莱德增持88.73万股",
    "href": "http://stock.jrj.com.cn/2021/11/10074933830384.shtml",
    "datetime": "2021-11-10 07:49:44",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获Wellington Management Group增持34.52万股",
    "href": "http://stock.jrj.com.cn/2021/11/04075133811136.shtml",
    "datetime": "2021-11-04 07:51:19",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)因可转债获转换发行10.67万股H股",
    "href": "http://stock.jrj.com.cn/2021/11/02171333803888.shtml",
    "datetime": "2021-11-02 17:13:15",
    "code": "603259"
  },
  {
    "title": "药明康德(2359.HK)高开4.27% 业绩略超预期",
    "href": "http://stock.jrj.com.cn/2021/11/01093033795406.shtml",
    "datetime": "2021-11-01 09:30:52",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)因可转债获转换发行5.927万股H股",
    "href": "http://stock.jrj.com.cn/2021/10/19173233717139.shtml",
    "datetime": "2021-10-19 17:32:08",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获美国资本集团增持147.37万股",
    "href": "http://stock.jrj.com.cn/2021/10/18081833708748.shtml",
    "datetime": "2021-10-18 08:18:49",
    "code": "603259"
  },
  {
    "title": "药明康德6名股东合计减持30.68万股 套现合计4465.98万 上半年公司净利26.75亿",
    "href": "http://stock.jrj.com.cn/2021/10/08214733659793.shtml",
    "datetime": "2021-10-08 21:47:15",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：多名董高完成减持30.68万股",
    "href": "http://stock.jrj.com.cn/2021/10/08201733659227.shtml",
    "datetime": "2021-10-08 20:17:25",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：子公司拟认缴1500万美元的投资基金份额",
    "href": "http://stock.jrj.com.cn/2021/09/27162233524117.shtml",
    "datetime": "2021-09-27 16:22:36",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获Wellington Management Group LLP增持18.56万股",
    "href": "http://stock.jrj.com.cn/2021/09/21071133480608.shtml",
    "datetime": "2021-09-21 07:11:26",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：减持数过半 多名董高已合计减持18.39万股",
    "href": "http://stock.jrj.com.cn/2021/09/17193133452963.shtml",
    "datetime": "2021-09-17 19:31:10",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获美国资本集团增持18.53万股",
    "href": "http://stock.jrj.com.cn/2021/09/10064133412242.shtml",
    "datetime": "2021-09-10 06:41:05",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行5.927万股",
    "href": "http://stock.jrj.com.cn/2021/09/07170233398924.shtml",
    "datetime": "2021-09-07 17:02:21",
    "code": "603259"
  },
  {
    "title": "ETF严选|药明康德涨超4%！券商齐声喊话错杀,医疗龙头获北向资金百亿巨资买入！",
    "href": "http://stock.jrj.com.cn/2021/09/03135033379443.shtml",
    "datetime": "2021-09-03 13:50:50",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行8.3万股",
    "href": "http://stock.jrj.com.cn/2021/09/01165833368212.shtml",
    "datetime": "2021-09-01 16:58:45",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)回购注销部分限制性A股股票",
    "href": "http://stock.jrj.com.cn/2021/08/26232933327835.shtml",
    "datetime": "2021-08-26 23:29:57",
    "code": "603259"
  },
  {
    "title": "药明康德的豪横，你不懂",
    "href": "http://stock.jrj.com.cn/2021/08/24215633312140.shtml",
    "datetime": "2021-08-24 21:56:59",
    "code": "603259"
  },
  {
    "title": "药明康德涨超6%CRO概念走强，医疗ETF（512170）迎久违大涨",
    "href": "http://stock.jrj.com.cn/2021/08/24101433308590.shtml",
    "datetime": "2021-08-24 10:14:01",
    "code": "603259"
  },
  {
    "title": "“医械茅”反弹8%！机构：药明康德、迈瑞医疗等市值底部已现，无需恐慌",
    "href": "http://stock.jrj.com.cn/2021/08/23143333302474.shtml",
    "datetime": "2021-08-23 14:33:43",
    "code": "603259"
  },
  {
    "title": "药明康德：业绩增长难挽股东去意 一股东因违规减持遭立案调查",
    "href": "http://stock.jrj.com.cn/2021/08/19083933278100.shtml",
    "datetime": "2021-08-19 08:39:35",
    "code": "603259"
  },
  {
    "title": "药明康德、爱尔眼科跌超1%，医疗ETF（159828）微跌0.32%",
    "href": "http://stock.jrj.com.cn/2021/08/18144533273381.shtml",
    "datetime": "2021-08-18 14:45:25",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)遭贝莱德减持37.28万股",
    "href": "http://stock.jrj.com.cn/2021/08/18070433271454.shtml",
    "datetime": "2021-08-18 07:04:44",
    "code": "603259"
  },
  {
    "title": "摩通：上调药明康德(2359.HK)目标价至200港元 评级“增持”",
    "href": "http://stock.jrj.com.cn/2021/08/16165333260973.shtml",
    "datetime": "2021-08-16 16:53:26",
    "code": "603259"
  },
  {
    "title": "药明康德中期净利润同比增长超5成，上半年新增客户逾千家",
    "href": "http://stock.jrj.com.cn/2021/08/13103033247290.shtml",
    "datetime": "2021-08-13 10:30:01",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)上半年归母净利26.75亿元 同比增长55.8%",
    "href": "http://stock.jrj.com.cn/2021/08/13063733245809.shtml",
    "datetime": "2021-08-13 06:37:10",
    "code": "603259"
  },
  {
    "title": "全球客户服务需求持续强劲 药明康德上半年归母净利润同比增长55.8%",
    "href": "http://stock.jrj.com.cn/2021/08/12201933244726.shtml",
    "datetime": "2021-08-12 20:19:29",
    "code": "603259"
  },
  {
    "title": "药明康德2021年半年度净利26.75亿元 同比净利增加55.79%",
    "href": "http://stock.jrj.com.cn/2021/08/12191233244261.shtml",
    "datetime": "2021-08-12 19:12:58",
    "code": "603259"
  },
  {
    "title": "【公告抢先看】晚间重要公告：双汇发展上半年净利同比下降17％、药明康德上半年净利润26.75亿元",
    "href": "http://stock.jrj.com.cn/2021/08/12184233244027.shtml",
    "datetime": "2021-08-12 18:42:14",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：“合全药业全球研发中心及配套项目”拟延期",
    "href": "http://stock.jrj.com.cn/2021/08/12175633243729.shtml",
    "datetime": "2021-08-12 17:56:09",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：上半年净利增55.79%至26.75亿元",
    "href": "http://stock.jrj.com.cn/2021/08/12175133243706.shtml",
    "datetime": "2021-08-12 17:51:56",
    "code": "603259"
  },
  {
    "title": "药明康德：上半年净利润26.75亿元 同比增56%",
    "href": "http://stock.jrj.com.cn/2021/08/12175033243702.shtml",
    "datetime": "2021-08-12 17:50:28",
    "code": "603259"
  },
  {
    "title": "药明康德AH股齐跌 此前发布95亿港元股权激励方案",
    "href": "http://stock.jrj.com.cn/2021/08/12104233241694.shtml",
    "datetime": "2021-08-12 10:42:49",
    "code": "603259"
  },
  {
    "title": "【龙虎榜】药明康德8月6日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/08/06180833213710.shtml",
    "datetime": "2021-08-06 18:08:41",
    "code": "603259"
  },
  {
    "title": "【核心ETF午间热讯】CRO概念走弱，药明康德跌逾9%，医疗板块重挫3%",
    "href": "http://stock.jrj.com.cn/2021/08/06115433211944.shtml",
    "datetime": "2021-08-06 11:54:21",
    "code": "603259"
  },
  {
    "title": "正海生物、药明康德大跌，生物医药ETF(512290)跌超3%，抄底资金大举涌入",
    "href": "http://stock.jrj.com.cn/2021/08/06112033211925.shtml",
    "datetime": "2021-08-06 11:20:24",
    "code": "603259"
  },
  {
    "title": "芯片界“药明康德”20cm涨停！盈利在望，诺安加仓",
    "href": "http://stock.jrj.com.cn/2021/08/05082333205197.shtml",
    "datetime": "2021-08-05 08:23:10",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获FMR LLC增持12.29万股",
    "href": "http://stock.jrj.com.cn/2021/08/04064833198631.shtml",
    "datetime": "2021-08-04 06:48:28",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)遭贝莱德减持98.14万股",
    "href": "http://stock.jrj.com.cn/2021/08/04064533198620.shtml",
    "datetime": "2021-08-04 06:45:44",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)建议采纳2021年H股奖励信托计划",
    "href": "http://stock.jrj.com.cn/2021/08/03063933191782.shtml",
    "datetime": "2021-08-03 06:39:48",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：14.46万份股票期权拟行权",
    "href": "http://stock.jrj.com.cn/2021/08/02192433190335.shtml",
    "datetime": "2021-08-02 19:24:47",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：拟推2021年股东利益一致性奖励计划",
    "href": "http://stock.jrj.com.cn/2021/08/02192333190329.shtml",
    "datetime": "2021-08-02 19:23:11",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：聘任Minzhang Chen(陈民章)博士为联席首席执行官",
    "href": "http://stock.jrj.com.cn/2021/08/02190533190263.shtml",
    "datetime": "2021-08-02 19:05:11",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行13.04万股",
    "href": "http://stock.jrj.com.cn/2021/07/30175833176195.shtml",
    "datetime": "2021-07-30 17:58:52",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)8月12日召开董事会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2021/07/29163633169867.shtml",
    "datetime": "2021-07-29 16:36:19",
    "code": "603259"
  },
  {
    "title": "股价上涨1.7倍 药明康德大股东计划减持近3000万股",
    "href": "http://stock.jrj.com.cn/2021/07/27094533157029.shtml",
    "datetime": "2021-07-27 09:45:00",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：Summer Bloom拟减持不超2952.5961万股",
    "href": "http://stock.jrj.com.cn/2021/07/26172933152893.shtml",
    "datetime": "2021-07-26 17:29:02",
    "code": "603259"
  },
  {
    "title": "药明康德AH股齐跌约4% 六名高管将减持33万股A股",
    "href": "http://stock.jrj.com.cn/2021/07/23133933139868.shtml",
    "datetime": "2021-07-23 13:39:41",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：拟认缴Sofinnova Capital X的2000万欧元的A类份额",
    "href": "http://stock.jrj.com.cn/2021/07/22163733135529.shtml",
    "datetime": "2021-07-22 16:37:09",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：6名董监高拟合计减持不超33.09万股A股",
    "href": "http://stock.jrj.com.cn/2021/07/22162933135489.shtml",
    "datetime": "2021-07-22 16:29:22",
    "code": "603259"
  },
  {
    "title": "药明康德、爱尔眼科、通策医疗跌逾2%，2季度均获得公募大手笔增资",
    "href": "http://stock.jrj.com.cn/2021/07/22113133134412.shtml",
    "datetime": "2021-07-22 11:31:24",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)遭贝莱德减持45.3万股",
    "href": "http://stock.jrj.com.cn/2021/07/21074733127769.shtml",
    "datetime": "2021-07-21 07:47:03",
    "code": "603259"
  },
  {
    "title": "安信证券：药明康德半年报业绩超预期增长，给予“买入”评级",
    "href": "http://stock.jrj.com.cn/2021/07/20074233122261.shtml",
    "datetime": "2021-07-20 07:42:03",
    "code": "603259"
  },
  {
    "title": "药明康德2021年上半年预计净利增加9.1亿-9.44亿 二季度销售收入持续强劲增长",
    "href": "http://stock.jrj.com.cn/2021/07/19193333120414.shtml",
    "datetime": "2021-07-19 19:33:59",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行37.93万股",
    "href": "http://stock.jrj.com.cn/2021/07/19181033120046.shtml",
    "datetime": "2021-07-19 18:10:09",
    "code": "603259"
  },
  {
    "title": "药明康德：上半年净利润预计同比增长53%-55%",
    "href": "http://stock.jrj.com.cn/2021/07/16094333105950.shtml",
    "datetime": "2021-07-16 09:43:00",
    "code": "603259"
  },
  {
    "title": "药明康德AH股均创历史新高 上半年净利预增53%-55%",
    "href": "http://stock.jrj.com.cn/2021/07/16092633105723.shtml",
    "datetime": "2021-07-16 09:26:59",
    "code": "603259"
  },
  {
    "title": "药明康德净利润预增五成 两大核心业务仍被看好",
    "href": "http://stock.jrj.com.cn/2021/07/16083533105909.shtml",
    "datetime": "2021-07-16 08:35:00",
    "code": "603259"
  },
  {
    "title": "药明康德2021年上半年预计净利增加9.1亿-9.44亿增长53%-55% 二季度销售收入增长",
    "href": "http://stock.jrj.com.cn/2021/07/15200633105555.shtml",
    "datetime": "2021-07-15 20:06:50",
    "code": "603259"
  },
  {
    "title": "药明康德：预计上半年净利润同比增长53%-55%",
    "href": "http://stock.jrj.com.cn/2021/07/15165433102172.shtml",
    "datetime": "2021-07-15 16:54:04",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)半年度净利润预增53%到55%",
    "href": "http://stock.jrj.com.cn/2021/07/15165033102160.shtml",
    "datetime": "2021-07-15 16:50:58",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行139.9万股",
    "href": "http://stock.jrj.com.cn/2021/07/13061833085161.shtml",
    "datetime": "2021-07-13 06:18:38",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据股份期权计划行使期权发行13.405万股",
    "href": "http://stock.jrj.com.cn/2021/07/13061533085143.shtml",
    "datetime": "2021-07-13 06:15:16",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)：2478万港元奖励已授予参与者 涉及13.5万股H股",
    "href": "http://stock.jrj.com.cn/2021/07/02184233034671.shtml",
    "datetime": "2021-07-02 18:42:39",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)创历史新高",
    "href": "http://stock.jrj.com.cn/2021/07/01135033027084.shtml",
    "datetime": "2021-07-01 13:50:41",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持327.99万股",
    "href": "http://stock.jrj.com.cn/2021/06/30095733020194.shtml",
    "datetime": "2021-06-30 09:57:38",
    "code": "603259"
  },
  {
    "title": "药明康德出手！被曝减持兄弟公司配售2300万股，套现约6.7亿！这家抗癌巨头应声暴跌14%……",
    "href": "http://stock.jrj.com.cn/2021/06/30080033019730.shtml",
    "datetime": "2021-06-30 08:00:30",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行20.15万股H股",
    "href": "http://stock.jrj.com.cn/2021/06/29185733017059.shtml",
    "datetime": "2021-06-29 18:57:49",
    "code": "603259"
  },
  {
    "title": "药明康德附属计划在美国建设含原料药与制剂生产基地",
    "href": "http://stock.jrj.com.cn/2021/06/29131033015317.shtml",
    "datetime": "2021-06-29 13:10:35",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：826.004万股限制性股票将于7月1日上市流通",
    "href": "http://stock.jrj.com.cn/2021/06/25184932997683.shtml",
    "datetime": "2021-06-25 18:49:04",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)参股公司纳微科技(688690.SH)在科创板挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/06/23212332985170.shtml",
    "datetime": "2021-06-23 21:23:47",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：参股公司纳微科技登陆科创板",
    "href": "http://stock.jrj.com.cn/2021/06/23172032983678.shtml",
    "datetime": "2021-06-23 17:20:35",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行164.77万股H股",
    "href": "http://stock.jrj.com.cn/2021/06/22184932977468.shtml",
    "datetime": "2021-06-22 18:49:49",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：参股公司Ambrx登陆纽交所",
    "href": "http://stock.jrj.com.cn/2021/06/21164332969911.shtml",
    "datetime": "2021-06-21 16:43:26",
    "code": "603259"
  },
  {
    "title": "证券市场禁入新规下月实施 药明康德股东违规减持立案调查",
    "href": "http://stock.jrj.com.cn/2021/06/20065732960311.shtml",
    "datetime": "2021-06-20 06:57:19",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)：参股公司Lyell在纳斯达克挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/06/18215432957045.shtml",
    "datetime": "2021-06-18 21:54:25",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转债获转换发行461.2万股H股",
    "href": "http://stock.jrj.com.cn/2021/06/18184932955962.shtml",
    "datetime": "2021-06-18 18:49:45",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：参股公司Lyell登陆纳斯达克",
    "href": "http://stock.jrj.com.cn/2021/06/18183232955791.shtml",
    "datetime": "2021-06-18 18:32:59",
    "code": "603259"
  },
  {
    "title": "偷摸减持“跑路”遭遇监管升级 药明康德股东被立案调查",
    "href": "http://stock.jrj.com.cn/2021/06/18075832952084.shtml",
    "datetime": "2021-06-18 07:58:09",
    "code": "603259"
  },
  {
    "title": "药明康德股东被证监会立案调查，投资者索赔有望？",
    "href": "http://stock.jrj.com.cn/2021/06/18070332951966.shtml",
    "datetime": "2021-06-18 07:03:30",
    "code": "603259"
  },
  {
    "title": "药明康德股东上海瀛翊遭证监会立案调查，只因其违规减持近29亿元",
    "href": "http://stock.jrj.com.cn/2021/06/17100132945957.shtml",
    "datetime": "2021-06-17 10:01:01",
    "code": "603259"
  },
  {
    "title": "上海瀛翊违规减持29亿元药明康德：被证监会调查",
    "href": "http://stock.jrj.com.cn/2021/06/16204832942412.shtml",
    "datetime": "2021-06-16 20:48:18",
    "code": "603259"
  },
  {
    "title": "违规减持近30亿元 药明康德一股东遭立案调查",
    "href": "http://stock.jrj.com.cn/2021/06/16204332942637.shtml",
    "datetime": "2021-06-16 20:43:00",
    "code": "603259"
  },
  {
    "title": "突发！4000亿白马股股东\"偷偷\"套现30亿，刚刚，证监会立案调查！",
    "href": "http://stock.jrj.com.cn/2021/06/16201332942197.shtml",
    "datetime": "2021-06-16 20:13:35",
    "code": "603259"
  },
  {
    "title": "药明康德：因涉嫌信披违法违规 证监会决定对上海瀛翊立案调查",
    "href": "http://stock.jrj.com.cn/2021/06/16184632941777.shtml",
    "datetime": "2021-06-16 18:46:44",
    "code": "603259"
  },
  {
    "title": "药明康德AH齐跌 因股东违规减持收上交所监管函",
    "href": "http://stock.jrj.com.cn/2021/06/16135332940193.shtml",
    "datetime": "2021-06-16 13:53:05",
    "code": "603259"
  },
  {
    "title": "药明康德陷入舆论漩涡，股东致歉因违规减持套现近29亿元",
    "href": "http://stock.jrj.com.cn/2021/06/16094932939222.shtml",
    "datetime": "2021-06-16 09:49:48",
    "code": "603259"
  },
  {
    "title": "华为将开5G+AR大会；13连板新股提示风险；药明康德收上交所监管工作函；杭可科技解除与宁德时代4.8亿合同",
    "href": "http://stock.jrj.com.cn/2021/06/16080832938761.shtml",
    "datetime": "2021-06-16 08:08:35",
    "code": "603259"
  },
  {
    "title": "上交所向药明康德和上海瀛翊：要求制定补偿措施",
    "href": "http://stock.jrj.com.cn/2021/06/15222032937089.shtml",
    "datetime": "2021-06-15 22:20:41",
    "code": "603259"
  },
  {
    "title": "药明康德因股东违规减持收监管函：要求股东尽快制定必要和充分的补偿措施",
    "href": "http://stock.jrj.com.cn/2021/06/15200232936451.shtml",
    "datetime": "2021-06-15 20:02:57",
    "code": "603259"
  },
  {
    "title": "不到三年股东套现超200亿元，如今违规减持再吸血30亿，这家4000亿巨头只给投资者一封道歉信……",
    "href": "http://stock.jrj.com.cn/2021/06/15152032934372.shtml",
    "datetime": "2021-06-15 15:20:45",
    "code": "603259"
  },
  {
    "title": "暴走A股药明康德股东违规减持29亿，这就么算了？",
    "href": "http://stock.jrj.com.cn/invest/2021/06/15103532933112.shtml",
    "datetime": "2021-06-15 10:35:31",
    "code": "603259"
  },
  {
    "title": "药明康德股东上海瀛翊减持违规29亿元：股价下跌2%",
    "href": "http://stock.jrj.com.cn/2021/06/15102932933091.shtml",
    "datetime": "2021-06-15 10:29:20",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733144767.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733157444.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733188260.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072732977715.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733128921.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733087221.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733139654.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733168979.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733198020.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733112002.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733178796.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德市值年增1900亿 股东违反承诺减持套现29亿",
    "href": "http://stock.jrj.com.cn/2021/06/15072733696522.shtml",
    "datetime": "2021-06-15 07:27:05",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：上海瀛翊违反承诺减持股份 减持总金额达28.94亿元",
    "href": "http://stock.jrj.com.cn/2021/06/14143432924590.shtml",
    "datetime": "2021-06-14 14:34:58",
    "code": "603259"
  },
  {
    "title": "突发：4000亿药明康德炸锅了！股东没公告就\"偷偷\"减持近30亿，一句道歉就完了？散户怒了：没收\"非法所得\"",
    "href": "http://stock.jrj.com.cn/2021/06/12070232915272.shtml",
    "datetime": "2021-06-12 07:02:05",
    "code": "603259"
  },
  {
    "title": "对标药明康德和泰格医药，第三方商业化平台百洋医药价值几何",
    "href": "http://stock.jrj.com.cn/2021/06/11131132910568.shtml",
    "datetime": "2021-06-11 13:11:57",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)根据零息可转换债获转换发行5.9万股H股",
    "href": "http://stock.jrj.com.cn/2021/06/08184232894810.shtml",
    "datetime": "2021-06-08 18:42:13",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：239.0426万份股票期权符合行权条件",
    "href": "http://stock.jrj.com.cn/2021/06/03194032870537.shtml",
    "datetime": "2021-06-03 19:40:55",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：2020年度拟10转2派3.63元 6月7日股权登记",
    "href": "http://stock.jrj.com.cn/2021/06/01185032858500.shtml",
    "datetime": "2021-06-01 18:50:03",
    "code": "603259"
  },
  {
    "title": "药明康德AH齐涨 资金追捧 机构唱多",
    "href": "http://stock.jrj.com.cn/2021/05/25113832815702.shtml",
    "datetime": "2021-05-25 11:38:42",
    "code": "603259"
  },
  {
    "title": "爱尔眼科、药明康德涨超2.7%，医疗板块午后发力拉升翻红",
    "href": "http://stock.jrj.com.cn/2021/05/21132732792841.shtml",
    "datetime": "2021-05-21 13:27:45",
    "code": "603259"
  },
  {
    "title": "药明康德附属拟认购药明汇英基金份额10亿元人民币",
    "href": "http://stock.jrj.com.cn/2021/05/21103132792143.shtml",
    "datetime": "2021-05-21 10:31:44",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)全资子公司拟认购私募基金份额10亿元",
    "href": "http://stock.jrj.com.cn/2021/05/20220232789412.shtml",
    "datetime": "2021-05-20 22:02:46",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)：调整2018年A股激励计划预留授予股票期权行权价格和数量",
    "href": "http://stock.jrj.com.cn/2021/05/20214732789352.shtml",
    "datetime": "2021-05-20 21:47:24",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)：子公司拟出资10亿元认购药明汇英基金份额",
    "href": "http://stock.jrj.com.cn/2021/05/20191432788682.shtml",
    "datetime": "2021-05-20 19:14:22",
    "code": "603259"
  },
  {
    "title": "迈瑞医疗涨6%，药明康德涨超5%，医疗板块大涨3%连续第7日上攻",
    "href": "http://stock.jrj.com.cn/2021/05/17103132768096.shtml",
    "datetime": "2021-05-17 10:31:18",
    "code": "603259"
  },
  {
    "title": "药明康德迎900亿限售股解禁，景顺长城基金一季度刚加仓",
    "href": "http://stock.jrj.com.cn/2021/05/10095232727225.shtml",
    "datetime": "2021-05-10 09:52:49",
    "code": "603259"
  },
  {
    "title": "下周解禁市值超1700亿，药明康德解禁超900亿元！这些股票解禁压力大（附名单）",
    "href": "http://stock.jrj.com.cn/2021/05/09093032718383.shtml",
    "datetime": "2021-05-09 09:30:41",
    "code": "603259"
  },
  {
    "title": "[加急]下周解禁总量约41.6亿股，药明康德解禁市值达907亿元",
    "href": "http://stock.jrj.com.cn/2021/05/09091932718377.shtml",
    "datetime": "2021-05-09 09:19:36",
    "code": "603259"
  },
  {
    "title": "解禁潮来袭！下周解禁市值超1700亿，药明康德解禁超900亿元！这些股票解禁压力大（附名单）",
    "href": "http://stock.jrj.com.cn/2021/05/09091432718361.shtml",
    "datetime": "2021-05-09 09:14:05",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获摩根大通增持93.38万股",
    "href": "http://stock.jrj.com.cn/2021/05/05075032660280.shtml",
    "datetime": "2021-05-05 07:50:32",
    "code": "603259"
  },
  {
    "title": "五月A股解禁市值增至4271亿元 药明康德占近四分之一",
    "href": "http://stock.jrj.com.cn/2021/05/01072732502353.shtml",
    "datetime": "2021-05-01 07:27:45",
    "code": "603259"
  },
  {
    "title": "五月解禁市值增至4271亿元 药明康德占近四分之一",
    "href": "http://stock.jrj.com.cn/2021/04/30214332489699.shtml",
    "datetime": "2021-04-30 21:43:00",
    "code": "603259"
  },
  {
    "title": "药明康德(603259.SH)一季度净利润升394.92%至15亿元",
    "href": "http://stock.jrj.com.cn/2021/04/29205032482272.shtml",
    "datetime": "2021-04-29 20:50:25",
    "code": "603259"
  },
  {
    "title": "【公告抢先看】晚间重要公告：广汇汽车与中国平安签订战略合作框架协议、药明康德一季度净利润同比增长395%",
    "href": "http://stock.jrj.com.cn/2021/04/29182432481113.shtml",
    "datetime": "2021-04-29 18:24:00",
    "code": "603259"
  },
  {
    "title": "药明康德：一季度净利15亿元 同比增395%",
    "href": "http://stock.jrj.com.cn/2021/04/29180032480898.shtml",
    "datetime": "2021-04-29 18:00:14",
    "code": "603259"
  },
  {
    "title": "药明康德：一季度净利15亿元 同比增395%",
    "href": "http://stock.jrj.com.cn/2021/04/29180032480894.shtml",
    "datetime": "2021-04-29 18:00:02",
    "code": "603259"
  },
  {
    "title": "药明康德(02359.HK)获贝莱德增持35.34万股",
    "href": "http://stock.jrj.com.cn/2021/04/20075532406911.shtml",
    "datetime": "2021-04-20 07:55:13",
    "code": "603259"
  }
]